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Abstract
Background: For almost 2000 years it has been recognized that aqueous extracts from pine cones
possess medicinal properties beneficial for the treatment of a broad variety of diseases and
conditions. In this report, the ability of an orally administered poly phenylpropanoid-polysaccharide
rich extract of pine cones (PPC) to suppress the generation of IgE and to significantly enhance
antigen-specific cellular responses to a variety of vaccines was tested.
Methods:  A variety of vaccine protocols were utilized to determine the affects of orally
administered PPC on the Th1/Th2 cytokine balance, the production of IgE antibodies, and the
generation of antigen-specific cytotoxic T cells. The effect of PPC on the Th1/Th2 balance in aged
mice was also investigated.
Results: Oral delivery of PPC was found to significantly suppress serum IgE levels in naïve mice
and in mice sensitized to ovalbumin. PPC was also found to enhance the generation of antigen-
specific CD8+ T cells in mice immunized with DNA, dendritic cell, and soluble protein vaccines. The
suppression of IgE was associated with reduction of IL-4 secretion and the enhanced production of
IL-12 and IFNγ by antigen-stimulated splenocytes from PPC treated mice. PPC also suppressed the
Th2 response and enhanced the Th1 response of splenocytes from aged mice.
Conclusion: Oral delivery of PPC enhances the generation of an antigen-specific CD8+ T cell
responses induced by soluble protein, DNA, and dendritic cell vaccines while at the same time
suppressing the generation of a Th2 dominant IgE response. This effect on the Th1/Th2 balance was
also observed in aged mice.
Background
Almost 2000 years ago the knowledge that aqueous
extracts of pine cones possessed medical properties was
first recorded [1,2]. For much of the last century the Japa-
nese inhabitants on the island of Kyushu have also known
about the medicinal properties of pine cones. They have
used a pine cone tea to treat illnesses ranging from colds
to cancer [3]. Because of the beliefs that the pine cone tea
Published: 30 November 2009
BMC Complementary and Alternative Medicine 2009, 9:49 doi:10.1186/1472-6882-9-49
Received: 28 August 2009
Accepted: 30 November 2009
This article is available from: http://www.biomedcentral.com/1472-6882/9/49
© 2009 Burrows et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
Page 2 of 12
(page number not for citation purposes)
is able to treat such a broad range of illnesses, it was
hypothesized by us that the effects of the extract were
likely being mediated through the immune system.
PPC is a poly-phenylpropanoid-polysaccharide complex
prepared from a single species of pine cones [4]. Proligna™
is a proprietary powder form of PPC that has been manu-
factured by Allera Health Products, Inc. (St. Petersburg,
FL) and is commercially available as Immune Extra™. The
polysaccharide component is composed of mannose,
fucose, arabinose, galactose, glucose, and uronic acids [5].
The extraction method used to prepare PPC is highly
reproducible as determined by UV spectroscopy, FPLC,
and biological assays.
In investigations where the toxicity of PPC has been exam-
ined in mice, oral administration at doses as high as 1.83
g/kg produce no noticeable toxic effects [6,7]. However, in
contrast to the apparent safety associated with oral admin-
istration of the extract, intravenous injection of mice with
one-thirtieth the oral dose was found to induce a toxic
shock-like syndrome and then death within two hours of
administration. The LD50 of the intravenously delivered
extract was found to be 52.5 and 56.0 mg/kg for male and
female mice [8]. Orally effective concentrations of PPC
have been determined in a variety of murine vaccine stud-
ies and plateau at a dose of 40 mg/kg/day.
Tissue distribution of the orally administered extract (10
mg/kg) was examined by measuring the levels of
125iodine-labeled extract in a variety of murine tissues at
intervals of 3, 24, or 48 h after delivery [7]. After 3 h
approximately 61% of the recoverable radioactivity was
found in the stomach and small intestine while 6.6% was
recovered from the blood, 4.4% was recovered from the
liver, and 9.5% was recovered from the urine. Twenty-four
hours after delivery, 89% of the recoverable activity was
detected in the urine and feces [7]. These results suggest
that while the majority of the extract remains in the GI
tract and is excreted within 24 h, a small fraction might be
absorbed systemically.
While the pine cone extract has been traditionally used to
complement the treatment of a variety of illnesses, an
increasing number of people using the commercial prod-
uct have remarked that when taken on a daily basis it pro-
vides significant relief from, or even eliminates, their
allergy symptoms. Since numerous studies have demon-
strated a strong correlation between the reduction of
serum IgE levels and noticeable improvement in the well
being of people suffering from IgE-mediated allergies [9-
12] we sought to determine if PPC might be modulating
the production of IgE.
The results presented herein suggest that PPC might in fact
be able to reduce IgE levels in patients with allergy. Oral
administration of PPC was found to reduce serum IgE lev-
els in mice and to significantly suppress the development
of an allergen induced IgE response. Interestingly, the
potential of PPC to suppress IgE levels appears to be asso-
ciated with its ability to enhance the generation of a Th1 -
associated cellular immune response, a response demon-
strated to improve the activity of a variety of vaccine types.
Methods
Mice
Six week old female C57BL/6 and Balb/c mice were pur-
chased from Charles River Laboratories. Aged male
B6C3F1 mice (23-25 months old) were obtained from the
National Institute of Aging. The mice were maintained in
accord with the NIH Guide for the Care and Use of Labora-
tory Animals. Experimental procedures were performed in
accord with research protocols approved by the Tampa
Bay Research Institute's Institutional Animal Care and Use
Committee (Assurance number: A3062-01). The results
presented herein are from single experiments representa-
tive of the findings obtained from multiple replicates.
Preparation of PPC
Pine cones from Scotch pine (Pinus sylvestris) were washed
extensively in deionized water. The pine cones were then
loaded into a stainless steel reaction vessel and extracted
with water at elevated pH and high temperature. The
resulting extract was standardized by visible and UV spec-
troscopy and by a series of biological assays. The liquid
was tested extensively to ensure that it did not contain
contaminants such as herbicides, pesticides, heavy metals,
or microorganisms and was then spray dried to form a
dark brown, odorless, stable powder (Proligna™). The
over the counter form, marketed as Immunextra®, consists
of 16 mg Proligna™ and 200 mg microcrystalline cellulose
in a vegetarian capsule. Product stability and potency are
tested by independent laboratories. Allera Health Prod-
ucts, Inc. complies with FDA guidelines for manufacturing
dietary supplements in the United States and is a member
of the Natural Products Association.
The powdered form of PPC, Proligna™, was obtained from
Allera Health Products Inc. (St. Petersburg, FL), sus-
pended in sterile water to a stock concentration of 25 mg/
mL (w/v), centrifuged at 10,000 × g for 20 minutes and
then filtered through a 0.2 μm nylon filter. The stock solu-
tion was diluted in sterile distilled water to prepare as
drinking water for the mice.
Immunizations
Female C57BL/6 mice were injected subcutaneously with
either 100 μg of ovalbumin (Grade V, Sigma Chemical
Co, St. Louis, MO) or 500 μg ovalbumin along with either
100  μg CpG (ODN 1826) (provided by Mayo Clinic
Molecular Core, Rochester MN) or 50 μg poly I:C (Sigma
Chemical Co., St. Louis, MO) formulated in IFA on day 0BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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(priming) and then again on day 14 (boost). In one set of
experiments female Balb/c mice were injected i.p. with 10
μg ovalbumin formulated in 2 mg Imject alum (Thermo
Fisher Scientific, Rockford, IL) on day 0 (prime) and again
on day 14 (boost).
Cell lines
Generation of BM-DC
Hind limbs of C57BL/6 mice were harvested and bone
marrow was isolated. Bone marrow derived dendritic cells
(BM-DC) were generated by plating bone marrow cells at
1 × 106 cells/mL in RPMI media (Invitrogen, Carlsbad,
CA) supplemented with 10% FCS (Invitrogen) for 7 days
with murine GM-CSF (10 ng/mL) and murine IL-4 (5 ng/
mL) (Peprotech, Rocky Hill, NJ). Media was replaced peri-
odically and fresh GM-CSF and IL-4 was added to the
cells. At day 7, BM-DC were harvested and replated at 2 ×
106 cells/mL with 1 μg/mL of LPS to induce maturation
overnight. On day 8, BM-DC were harvested and pulsed
with 10 μg/mL of peptide for 2 hours at 37°C and 5%
CO2.
DC Vaccine
C57BL/6 mice (3 per group) were immunized by i.v. injec-
tions with 2 × 106  LPS-matured BM-DC, pulsed with
either the MHC-Class I (H-2Kb) restricted OVA257-264
(SIINFEKL) or Trp2180-188 (SVYDFFVWL) peptides (A&A
Labs., San Diego, CA). Each mouse received the DC vac-
cine injections on days 0, 7, and 14. For some groups, PPC
(200 μg/mL) was added in the drinking water, beginning
24 hours before the first vaccination and continued
throughout the period of the study.
DNA Vaccination
Mice (3 per group) were immunized with a total of 100 μg
of plasmid DNA suspended in 100 μL normal saline. A
total of 50 μL of the DNA solution was then injected into
each of 2 sites in the quadriceps femoris muscles. Immuni-
zation was followed immediately by electroporation of
the injected area (95 volts in four pulses of 65 millisec-
onds) using an Electro Square Porator device (BTX, model
TX830). All groups of mice were vaccinated twice with a 2
week interval. Some groups of mice received 200 μg/mL
PPC in their drinking water, starting 24 hours before the
first vaccination and continuing throughout the duration
of experiment.
Detection of serum IgE
Serum from mice was analyzed by ELISA using the anti-
body kit from Bethyl Laboratories (Montgomery, TX) and
following the manufacturer's instructions. The sensitivity
of the assay was 3.9 ng/mL for murine IgE. Assays were
performed in 96 well flat bottom Maxisorp plates (Nunc;
Thermo Fisher Scientitific, Rochester, NY) using serum
diluted 1:10 with 50 mM Tris, 0.14 M NaCl, 1% BSA, and
0.05% Tween 20.
Detection of OVA-specific IgG2a
Maxisorp 96 well flat-bottom plates were coated with 100
μg/mL ovalbumin in carbonate-bicarbonate buffer
(Sigma) overnight at 10°C. The plates were washed with
PBS containing 0.05% Tween-20 (PBST) and then
blocked by adding 300 μL StartingBlock (Pierce Scientific,
Rockford, IL) to each well for 10 min. This was removed
and 2-fold serial dilutions of the serum samples, ranging
from 1:250 to 1:32,000, in PBS containing 1% bovine
serum albumin were added in triplicate to appropriate
wells and incubated overnight at 10°C. After the over-
night incubation the wells were washed 4 times with PBST
and then horseradish peroxidase-conjugated goat anti-
mouse IgG2a  antibody (cat no. M32307, Invitrogen,
Carlsbad, CA), diluted 1:2000, was added to each well for
1 h at room temperature. The wells were washed with
PBST and then 100 μl of the SureBlue substrate (KPL, Inc.,
Gaithersburg, MD) was added. The color reaction was
stopped by adding 50 μL of 2 M H2SO4 or 1 M HCl and
the absorbance was read at 450 nm.
Splenocyte isolation
To prepare single cell suspensions of splenocytes the
spleens were isolated using aseptic technique, placed in
sterile polypropylene bags containing 5 mL of incomplete
media (RPMI 1640), and homogenized in a Stomacher 80
Laboratory Blender (Seward Medical, London, England)
at high setting for 60 seconds. The resulting cell suspen-
sion was filtered through a 70 μm nylon and then mixed
with 5 mL of 2× ACK lysis buffer (1× ACK lysis buffer is
8.29 g/L NH4Cl, 1 g/L KHCO3, and 37.2 mg/L Na2EDTA,
pH 7.2) for 5 minutes at room temperature to remove the
RBC. The splenocytes were pelleted and then suspended
in complete media (RPMI 1640 containing 10% fetal calf
serum, 4 mM L-glutamine, and 50 μM β-2 mercaptoetha-
nol) to a final concentration of 1 × 106 per mL. The cell
count and viability was performed using the trypan blue
dye exclusion method. The viability of the cells was typi-
cally >95%.
Splenocyte cultures for cytokine production
One milliliter of splenocytes, at a concentration of 1 × 106
cells/mL (from aged B6C3F1 mice) was plated in each of
six wells of a 24 well plate. To enhance cytokine produc-
tion in the splenocyte culture, 50 μL of a 100 μg/mL solu-
tion of concanavalin A (ConA) was added to 3 of the 6
wells. After 48 hours of incubation at 37°C in an atmos-
phere containing 5% CO2, the culture media was removed
and placed in a sterile 1.5 mL microcentrifuge. The media
was cleared of cells and debris by centrifugation at 16,000
× g for 2 minutes. The cleared media was transferred to aBMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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sterile 1.5 microfuge tube and stored at -80°C until it was
analyzed by ELISA for cytokine levels.
Splenocytes from Balb/c mice that had been immunized
in the presence or absence of PPC were incubated in 24
well plates at a concentration of 4 × 106/mL for 48 h in the
presence of media alone, 100 μg/mL ovalbumin (Fraction
V, Sigma Chemical Company), or 10 ng/mL PMA + 100
ng/mL ionomycin. The 48 h supernatants were cleared of
cells and then analyzed by ELISA for the presence of
appropriate cytokines.
IFNγ ELISPOT
For detection of CD8+  T cells secreting IFNγ, enzyme
linked immunosorbent spot (ELISPOT) assays were per-
formed. Briefly, Millipore Multiscreen Plates were coated
by overnight incubation at 4-10°C with 100 μl of 5 μg/mL
anti-mouse IFNγ (clone AN-18, eBioscience, Inc., San
Diego, CA) in PBS and then blocked by incubation for 3
h at 37°C with 200 μL RPMI-10 (RPMI 1640 with 10%
fetal bovine serum). Stimulator cells were washed once
with complete media and then suspended at a concentra-
tion of 3-5 × 106/mL. The appropriate peptide was then
added at a concentration of 20 μg/mL and the cells were
incubated for a minimum of 3 hours in a 5% CO2 atmos-
phere at 37°C. The stimulator cells were then irradiated at
10,000-20,000 Rads, depending on the cell line being
used. The stimulator cells were washed twice in RPMI-10
and then suspended in RPMI-10 to a concentration of 1 ×
106/mL. For the IFNγ ELISPOT assay, irradiated stimulator
cells (EL4 or EG7) were used to present endogenous OVA
or were pulsed with the Class I OVA peptide (SIINFEKL).
CD8+ T cells were purified from splenocytes of vaccinated
mice by positive selection using antibody-coated mag-
netic beads (Miltenyi Biotec, Auburn, CA). Responder
(CD8 purified) cells were incubated at different concen-
trations per well, together with 5 × 104 stimulator cells
(peptide pulsed, unpulsed, or expressing tumor cells).
Cultures were incubated at 37°C for 20 h. After the incu-
bation the cells were removed from the plate and the wells
washed 6 times with PBST. Then, 100 μL of biotinylated
anti-IFNγ at 1 μg/mL in PBST was added to each well, the
plate was covered and incubated 2-3 hours at room tem-
perature. The plate was then washed with PBST and 100
μL/well of avidin-HRP was added at a 1:1000 dilution in
PBST followed by incubated at room temperature for 1
hour. The plate was washed 6 times with PBST and then 3
times with PBS only. Freshly prepared 3-amino-9-ethyl-
carbazole (AEC) substrate (100 μL) was added to each
well and incubated for 10-30 minutes at room tempera-
ture. The plate was flooded with tap water to stop the
color development and then submerged in a tank of tap
water to assure low background. The plates were allowed
to dry overnight. Spot counting was performed with an
AID EliSpot Reader System (Autoimmune Diagnostika
GmbH).
Cytokine ELISA
The detection of the cytokines, IL-12p40, IFNγ, IL-4, and
IL-10 was performed using the murine cytokine develop-
ment kits from Peprotech (Rocky Hill, NJ). The IL-5 ELISA
was performed using the Ready-SET-Go kit from eBio-
science (San Diego, CA). The assays were performed fol-
lowing the manufacturer's instructions. The sensitivities
for the IL-12p40, IFNγ, IL-4, IL-5 and IL-10 ELISAs were,
32, 16, 16, 4, and 47 pg/mL, respectively.
Statistical Analysis
The results are expressed as means ± SD (standard devia-
tion). All assays were perform in triplicate and repeated at
least three times. The statistical difference between two
groups was determined by Students t test. When multiple
groups were being analyzed the statistical difference was
determined using the one-way analysis of variance
(ANOVA). A p-value < 0.05 was considered statistically
significant.
Results
Oral administration of PPC reduces total IgE levels in naïve 
mice
To determine if oral administration of PPC affected IgE
levels in mice, we administered a group of naive female
Balb/c mice (n = 4 per group) with 200 μg/mL of PPC in
their drinking water ad libitum for 14 days, after which, the
serum levels of total IgE were determined by ELISA. The
IgE levels in mice receiving PPC were found to be signifi-
cantly lower (p < 0.01) that those found in mice receiving
just water (Figure 1).
Continuous delivery of PPC suppresses the rise in serum 
IgE levels associated with sensitization to an allergen
C57BL/6 mice (4 per group) were injected s.c. on days 0
and 14 with 100 μg chicken egg ovalbumin (OVA) (Figure
2, left panel) or 500 μg of OVA formulated in IFA (Figure
2, right panel) to determine if oral delivery of PPC could
suppress the induction of an IgE response. The TLR lig-
ands, CpG (100 μg) and poly I:C (50 μg), were formulated
with the OVA and IFA and provided with both the prim-
ing and booster injections to serve as positive controls for
IgE inhibition. In the first experiment, groups of mice
received either 2, 20, or 200 μg of PPC by gavage at the
time of the priming and booster injections, or 200 μg/mL
PPC in the drinking water ad libitum, beginning immedi-
ately after the priming injection (Figure 2, left panel). In
the second set of experiments, groups of mice were pro-
vided PPC (20, 200, or 2000 μg/mL) ad libitum in their
drinking water beginning on day -1 and lasting until day
21, when the total serum IgE ELISA assays were performed
(Figure 2, right panel). The results demonstrate that deliv-BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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ery of PPC by gavage at the time of the initial sensitization
and then at the time of the booster inoculation had no sig-
nificant effect on the levels of serum IgE (p > 0.05 at all
three doses of PPC, left panel). However, when PPC was
provided ad libitum at 200 μg/mL, a highly significant sup-
pression of the allergen-associated increase in total IgE
levels was detected (Figure 2, left panel, p < 0.0001).
When the C57BL/6 mice were immunized with 500 μg
OVA formulated in IFA (Figure 2 right panel), a mixture
that biases a Th2 mediated response [13], PPC provided
ad libitum demonstrated no effect at 20 μg/mL (p > 0.05),
but was able to significantly suppress the IgE response at
200 and 2000 μg/mL (p < 0.001 at both doses). As antici-
pated, both of the positive controls, CpG and poly IC were
found to suppress the allergen-associated rise in IgE levels
(p < 0.001 for both, Figure 2, right panel).
Continuous delivery of PPC enhances the production of 
allergen-specific IgG2a
Since it appeared that PPC was capable of suppressing an
IgE response, a response known to be highly dependent
on the Th2-associated cytokine, IL-4, we sought to deter-
mine if PPC might be suppressing the Th2 response by
inducing the mutually inhibitory Th1 response. To do this
we measured the serum levels of OVA-specific IgG2a, an
isotype strongly associated with the presence of a Th1
Reduction of basal IgE in naïve mice Figure 1
Reduction of basal IgE in naïve mice. Naïve Balb/c mice 
(n = 4/group) were provided water or 200 μg/mL PPC ad libi-
tum for 14 days. The serum levels of total IgE were measured 
by ELISA. PPC suppressed the development of IgE (** repre-
sents a p < 0.01). Error bars represent the standard devia-
tion.
Suppressed induction of an IgE response Figure 2
Suppressed induction of an IgE response. Mice were injected s.c. on day 0 and day 14 with 100 μg OVA (left panel) or 
500 μg OVA formulated in IFA (right panel). CpG (100 μg s.c.) or poly I:C (50 μg s.c.) were delivered at the time of priming 
and booster injections to serve as positive controls. Mice in the left panel received 2, 20, or 200 μg PPC by gavage at the time 
of the priming and booster injections, or 200 μg/mL PPC in the drinking water ad libitum, beginning at the time of the priming 
injection. Mice in the right panel were provided PPC (20, 200, or 2000 μg/mL) ad libitum in their drinking water beginning on 
day -1 and lasting until day 21 when the total serum IgE ELISA assays were performed. All mice receiving PPC also received the 
OVA vaccine. Error bars represent the standard deviation. The (**) represents a p < 0.001 and (***) represents a p < 0.0001.BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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response. Sera obtained from the C57BL/6 mice immu-
nized with OVA + IFA were examined by ELISA (Figure 3).
When the mice were immunized with 500 μg OVA formu-
lated in IFA, PPC provided ad libitum at 20 μg/mL failed to
enhance the IgG2a response (p > 0.05). However, when
the mice received either 200 or 2000 μg/mL along with
vaccination, a significant increase in the production of
OVA-specific IgG2a antibodies was detected (p < 0.05 and
<0.01, respectively, Figure 3). The finding that the same
doses of PPC that suppress IgE production also enhanced
OVA-specific IgG2a levels, suggest that PPC alters the Th1/
Th2 balance. As expected, both of the TLR ligands were
found to enhance production of the OVA-specific IgG2a (p
< 0.001 for CpG and < 0.05 for poly IC).
Continuous delivery of PPC enhances an antigen-specific 
CD8+/IFNγ+ T cell response
To determine if the observed suppression of IgE and
enhancement of allergen-specific IgG2a were associated
with overall enhancement of a Th1-type response, we
determined whether PPC affected development of an
OVA-specific CD8+ T cell response. Splenic CD8+ T cells
were isolated on day 21 from C57BL/6 following immu-
nization with 500 μg OVA formulated in IFA. The TLR lig-
ands, CpG (100 μg) and poly IC (50 μg) were included in
the formulation to serve as positive controls for immune
modulators. Mice in three other groups (n = 4 per group)
were provided PPC (20, 200, or 2000 μg/mL) in their
drinking water beginning on day -1 and lasting until day
21 when an IFNγ ELISPOT analysis was performed (Figure
4). Both the CpG and poly I:C significantly enhanced the
CD8 response against OVA (p = 0.001 and 0.006, respec-
tively), while the delivery of PPC at 200 and 2000 μg/mL
more than doubled the response (Figure 4, p < 0.001 for
both doses). As was observed for its effects on IgE and
IgG2a, PPC provided at 20 μg/mL did not significantly
affect the CD8+ T cell response (p > 0.05). When compared
to CpG and poly I:C, the oral delivery of PPC at 200 and
2000 μg/mL was more effective at enhancing the OVA-
specific CD8+ T cell response (Figure 4).
Combined with the finding that PPC suppresses IgE levels
in mice, and that in mice this has been associated with ele-
vation of antigen-specific IgG2a and a doubling of the
number of antigen-specific CD8+/IFNγ T cells, these
results suggest that oral administration of PPC is capable
of significantly boosting a Th1-like response and that this
response, via the mutual inhibitory feedback mechanism,
could be responsible for suppressing the generation of a
Th2 response and the production of IgE.
Enhancement of OVA-specific IgG2a production Figure 3
Enhancement of OVA-specific IgG2a production. 
C57BL/6 mice (4/group) were injected s.c. on day 0 and day 
14 with 500 μg OVA formulated in IFA. CPG (100 μg s.c.) or 
poly I:C (50 μg s.c.) were delivered at the time of priming and 
booster injections to serve as positive controls. Mice were 
provided PPC (20, 200, or 2000 μg/mL) ad libitum in their 
drinking water beginning on day -1 and lasting until day 21 
when the OVA-specific IgG2a ELISA assays were performed. 
Error bars represent the standard deviation. The (*) repre-
sents a p < 0.05, the (**) represents a p < 0.01, and (***) rep-
resents a p < 0.001.
PPC enhances the production of IFNγ+/CD8+ T cells in  response to a protein vaccine Figure 4
PPC enhances the production of IFNγ+/CD8+ T cells 
in response to a protein vaccine. C57BL/6 mice (4/
group) were injected s.c. on day 0 and day 14 with 500 μg 
OVA formulated in IFA. CPG (100 μg) or poly I:C (50 μg) 
was included in the priming and booster injections to serve 
as positive controls. Other mice were provided PPC (20, 
200, or 2000 μg/mL) in their drinking water beginning on day 
7 and lasting until day 21 when the IFNγ ELISPOT analysis 
was performed. The number of spots (CD8+/IFNγ+ cells per 
105 isolated CD8+ cells) is shown. Error bars represent the 
standard deviation. The (*) represents a p < 0.006, while the 
(**) represents a p < 0.001.BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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PPC suppresses Th2-associated cytokine production by 
splenocytes from Balb/c mice sensitized to ovalbumin
To demonstrate that PPC could be affecting the Th1/Th2
balance, we examined cytokine production by female
Balb/c mice exposed to OVA. OVA (10 μg) formulated in
alum was injected i.p. on days 0 and 14. One group of
mice (OVA + PPC) received 200 μg/mL PPC in their drink-
ing water beginning 7 days prior to the first injection. On
day 28, fourteen days after the last OVA injection, the
serum levels of IgE were determined and the in vitro
cytokine production by OVA stimulated splenocytes was
examined (Figure 5). The results reveal that in this Th2
dominant mouse, oral administration of PPC signifi-
cantly suppressed the generation of IgE in response to the
immunization (p < 0.001) and suppressed the production
of IL-4 in response to OVA (p < 0.01). PPC also enhanced
the release of IFNγ significantly (p < 0.01) (Figure 5).
PPC enhances IL-12 and suppresses IL-4 and IL-10 
secretion by splenocytes from aged mice
To determine if PPC could affect the Th1/Th2 balance in a
very different immunologic model, we administered aged
B6C3F1 mice (23-25 month old males) with relatively
low levels of PPC (5 or 50 μg/mL) in their drinking water
ad libitum for 25 days. One group of mice received DHEAS
(dehydroepiandrosterone sulfate, 100 μg/mL) in their
drinking water as a positive control. DHEA serves as the
precursor to testosterone and estrogen and has been
reported to enhance the Th1 response in aged mice and
humans [14]. Each treatment group contained a total of
15 mice. After 25 days, 5 mice per group were randomly
selected and euthanized. The spleens were isolated and
converted to single cell suspensions, cultured in the pres-
ence of 5 μg/mL concanavalin A for 48 h, and then the cul-
ture supernatant was examined for the levels of Th1 and
Th2 cytokines (Figure 6). The results demonstrate that the
splenocytes from PPC treated mice produced significantly
less IL-4 (p < 0.01 for 5 μg/mL and < 0.001 for 50 μg/mL)
and IL-10 (p < 0.05 for 5 μg/mL and <0.01 for 50 μg/mL),
and significantly more IL-12p70 (p < 0.01 for both doses)
than splenocytes from untreated mice. At the low levels
provided, PPC did not appear to significantly affect the
amount of IFNγ in these mice.
These results demonstrate that the oral delivery of PPC
can modulate an immune response away from one that is
predominately Th2-mediated towards one that is Th1-
mediated. If this were the case, we would expect to find
that oral delivery of PPC would enhance the antigen-spe-
cific CD8+ T cell response to a variety of vaccine types and
suppress the development of IgE antibodies.
PPC affects the Th1/Th2 cytokine expression pattern Figure 5
PPC affects the Th1/Th2 cytokine expression pattern. Balb/c mice (4/group) were injected i.p. on day 0 and day 14 with 
10 μg OVA formulated in alum and then on day 28 the serum IgE levels were measured. Mice in the OVA + PPC group 
received 200 μg/mL of PPC in their drinking water beginning 7 days before (day -7) the first OVA injection and continued 
throughout the entire 28 day period. The serum IgE levels are shown for untreated (Naïve), OVA vaccinated (OVA) and PPC 
treated mice that had been vaccinated with OVA (OVA + PPC). The differences between the IgE and IL-4, and IFNγ levels in 
the OVA and OVA + PPC groups are significant (p < 0.001 and 0.01, 0.01, respectively). Error bars represent the standard 
deviation. The (**) represents a p < 0.01 while the (***) represents a p < 0.001.BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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PPC enhances the CD8+/IFNγ+ T cell response to a OVA-
specific DNA vaccine
Female C57BL/6 mice (4 per group) were immunized by
electroporation with plasmid DNA encoding full length
ovalbumin and then analyzed for the generation of IFNγ
CD8+ T cells specific for the dominant Class I epitope
(OVA257, SIINFEKEL).
While untreated mice produced 800 IFNγ spots per 106
isolated CD8+ T cells, co-administration of 200 μg/mL of
PPC more than doubled that number (1750). This effect
was significant (p = 0.009 for OVA257 peptide pulsed EL4
and 0.005 for the cells stimulated with EG7 cell) and anti-
gen-specific since the EL4 without peptide failed to stimu-
late IFNγ production (Figure 7).
PPC enhances the CD8+/IFNγ+ T cell response to a 
melanoma antigen-specific dendritic cell vaccine
Female C57BL/6 mice (4 per group) were immunized
weekly for three weeks by intravenous injection of 2 × 106
LPS-matured bone marrow derived dendritic cells that
had been pulsed with the melanoma-derived Trp2180-188
peptide (SVYDFFVWL). For some groups, PPC (200 μg/
mL) was added in the drinking water beginning 24 hours
before vaccination and continued throughout the period
of the study. Seven days following the last injection, CD8+
T cells were isolated from the spleen and analyzed via
ELISPOT for the antigen-specific production of IFNγ. As
shown in Figure 8, mice treated with PPC produced more
than double the number of antigen-specific CD8+/IFNγ+ T
cells (p = 0.002 for EL4 pulsed with Trp2180). The antigen-
specific nature of the response was clearly detected by the
lack of a response in the absence of the Trp2180-188 peptide
or in the presence of the irrelevant OVA257-264 peptide
(Figure 8, EL4 only and EL4 OVA, p = 0.1 for both groups).
Discussion
For centuries people have utilized a tea prepared from
pine cones to provide relief from a variety of ailments,
including cancer [3]. A description of the medicinal prop-
erties of an orally administered pine cone extract can even
be found in the De Materia Medica of Dioscorides, a five
book compilation on the preparation, properties, and
testing of drugs, written in A.D. 65, that was the basis for
pharmaceutical and herbal writing until the sixteenth cen-
tury [1,2].
Upon learning that consumers of the commercial pine
cone extract (Immune Extra™) had experienced a signifi-
cant reduction of their allergy symptoms we sought to
PPC affects the Th1/Th2 pattern of cytokine expression in aged mice Figure 6
PPC affects the Th1/Th2 pattern of cytokine expression in aged mice. Aged B6C3F1 mice were provided PPC (5 or 
50 μg/mL) or DHEAS (100 μg/mL) ad libitum for 25 days. The splenocytes from these mice were then cultured in the presence 
of 5 μg/mL concanavalin A for 48 h. The culture supernatant was examined by ELISA for the levels of IL-4, IL-10, IL-12, and 
IFNγ. Error bars represent the standard deviation. The (*) represents a p < 0.05, the (**) represents a p < 0.01, and the (***) 
represents a p < 0.001.BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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determine if the product affected the generation of IgE in
mice. It was observed that oral delivery of PPC was able to
reduce the basal levels of IgE in naive mice Balb/c mice
(Figure 1), a strain known to be Th2-biased and to pro-
duce elevated levels of IgE. When we stimulated a Th2
response in C57BL/6 mice by immunizing them with an
optimal amount of ovalbumin formulated in IFA, we
observed that in the presence of PPC the rise in IgE levels
was significantly suppressed (Figure 2). Interestingly, the
dose response pattern of IgE suppression observed in the
immunized mice was reflected in the ability of PPC at 200
and 2000 μg/mL, but not 20 μg/mL, to significantly
increase the production of OVA-specific IgG2a (Figure 3)
and the production of OVA-specific IFNγ/CD8+ T cells
(Figure 4). This biasing of the antigen-specific response
from one that was Th2-dominant (increased IgE) in the
untreated mice to one that was Th1-dominant (sup-
pressed IgE and an increased IgG2a and CD8 response) in
the PPC treated mice suggested that PPC is likely to be
beneficial in disease processes where it would be advanta-
geous to either enhance Th1 or suppress Th2 responses.
To determine if the administration of PPC could be in fact
beneficial in instances where Th1 enhancement or Th2
suppression were appropriate, we tested its ability to affect
the Th1/Th2 balance in the aged and in a variety of vac-
cine models.
It has been recognized that as the human population ages
the incidence of disease increases and the ability of our
immune systems to protect us from infectious diseases
and cancer, or to respond to vaccines wanes [15]. At the
same time, the incidence of autoimmune diseases and
allergies tends to increase [16-21]. These observations,
and the detection of increased levels of the key Th2
cytokine, IL-4, in aged humans and mice, demonstrates
that in the aged there is a shift in the Th1/Th2 balance
towards responses that tends to be Th2 dominant. Unfor-
tunately, Th2 dominant responses are not very effective at
protecting us against infections and cancer, and in some
cases of autoimmunity, can even be pathologic.
To determine if PPC can influence the Th1/Th2 balance in
the aged, we provided aged mice with PPC in their drink-
ing water for 25 days and then activated their splenocytes
in vitro. The splenocytes from the PPC treated mice were
found to produce significantly lower levels of IL-4 and IL-
PPC enhanced the IFNγ+/CD8+ T cell response to a DNA  vaccine specific for ovalbumin Figure 7
PPC enhanced the IFNγ+/CD8+ T cell response to a 
DNA vaccine specific for ovalbumin. PPC enhanced the 
DNA vaccine induced production of OVA-specific IFNγ+/
CD8+ T cells. Mice were immunized by DNA injection fol-
lowed immediately by electroporation. Mice were injected 
with DNA encoding full-length ovalbumin and then the injec-
tion area was immediately exposed to 95 volts in four pulses 
of 65 milliseconds using an Electro Square Porator device 
(BTX, model TX830). CD8+ T cells were isolated from the 
splenocytes population and plated with stimulator cells (EL4 
only, EL4 pulsed with the OVA257 peptide, or EG7 cells). 
Mice receiving no PPC are represented by the open bars 
while those receiving 200 μg/mL PPC ad libitum are repre-
sented by the filled bars. Error bars represent the standard 
deviation. The delivery of PPC was found to significantly 
enhance the number OVA specific IFNγ+/CD8+ T cells (p = 
0.009 for EL4 OVA257 and p = 0.005 for EG7).
PPC enhanced the IFNγ+/CD8+ T cell response to a dendritic  cell vaccine specific for a melanoma antigen Figure 8
PPC enhanced the IFNγ+/CD8+ T cell response to a 
dendritic cell vaccine specific for a melanoma anti-
gen. PPC enhanced the dendritic cell vaccine induced pro-
duction of melanoma associated Trp2-specific IFNγ+/CD8+ T 
cells. CD8+ T cells were isolated from the splenocytes popu-
lation and plated with stimulator cells (EL4 only, EL4 pulsed 
with the Trp2180 peptide, or EL4 pulsed with the irrelevant 
OVA257 peptide). Mice receiving no PPC are represented by 
the open bars while those receiving 200 μg/mL PPC ad libi-
tum are represented by the filled bars. Error bars represent 
the standard deviation. The delivery of PPC was found to sig-
nificantly enhance the number Trp2180 specific IFNγ+/CD8+ T 
cells (p = 0.002 for EL4 Trp2180).BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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10 and higher levels of IL-12p70 that those from the non-
treated mice (Figure 7). These results indicated that the
Th1/Th2 balance in the aged could be affected by oral
administration of PPC. Interestingly, even though IL-
12p70 levels were elevated in ConA-stimulated spleno-
cytes cultures from the PPC- and DHEAS-treated mice, we
failed to detect a significant enhancement of IFNγ in these
cultures. The finding that splenocytes from the DHEAS
treated mice also failed to induce IFNγ in the presence of
elevated IL-12p70 levels suggests that the lack of IFNγ
response was not specifically associated with PPC. In a
parallel experiment (not shown), young B6C3F1 mice
were also treated with DHEAS and PPC. The ConA-stimu-
lated splenocyte cultures from these mice were found to
produce significantly more IFNγ than the cultures from
the untreated mice. Also, the levels of IFNγ in the cultures
from the young naïve mice were much higher than that
found in the cultures prepared from the older naïve mice.
This suggests that some age-related phenomenon was pre-
venting the splenocytes from secreting IFNγ. Based on
these findings, further experiments will be performed to
determine if the suppression of IL-4 and IL-10, concurrent
with the enhancement of IL-12p70 production in the aged
mice translates into an increased cellular response to vac-
cines, resistance to infections, and reduction of IgE. The
findings from such experiments could be significantly
beneficial to the aging population of humans.
To demonstrate the biological relevance of PPC's ability to
enhance a Th1 response in younger mice, we examined its
influence on the development of antigen-specific CD8+ T
cell responses induced by DNA and dendritic cell vac-
cines. In both vaccine models it was discovered that oral
delivery of PPC more than doubled the number of anti-
gen-specific IFNγ+/CD8+ T cells generated by the vaccine
(Figures 7 and 8). The doubling of the antigen-specific
CD8+ T cell response was also observed in PPC treated
mice immunized with a soluble whole protein vaccine
(Figure 4). These results strongly suggest that orally
administered PPC can function as a potent adjuvant for
protein, DNA, and dendritic cell vaccines encoding exog-
enous antigens. In these experiments CpG was included as
a positive control and was found to suppress IgE produc-
tion while boosting the IgG2a response to an extent greater
than PPC. However, when the effects of PPC and CpG on
the production of antigen-specific CD8+/IFNγ+ T cells was
examined, PPC treated mice appeared to produce greater
numbers of these cells. Since PPC is a crude extract likely
to contain hundreds or thousands of different molecules,
the finding that it had a weaker effect on IgE suppression
and IgG2a enhancement than CpG, while having a greater
effect on the production of CD8+/IFNγ+ T cells, is not that
surprising. The mixture of molecules in the crude product
could certainly result in synergistic, additive, and even
counteracting activities that ultimately produce an in vivo
response similar and different than purified immune
modulators. Further experiments need to be performed in
order to isolate the various activities in PPC and to deter-
mine the efficacy of using this product to enhance the cel-
lular response to a variety of vaccines targeting infectious
agents and cancer.
Our results have provided significant evidence that pro-
longed oral administration of PPC leads to the reduction
of serum IgE levels and the enhancement of cellular
immune responses. To determine how this might take
place we must consider the mechanisms that lead to IgE
production. The first step consists of signals that favor the
differentiation of naive Th0 cells to a Th2 phenotype,
while the second step comprises the action of cytokines
and co-stimulatory signals from Th2 cells that stimulate B
cells to switch to the production of IgE antibodies. The dif-
ferentiation of naive Th0 CD4 T cells is determined by the
cytokines they are exposed to before and during this
response, and by the intrinsic properties of the antigen,
antigen dose, and route of presentation. Naïve CD4 T cells
being primed by their first encounter with antigen pre-
senting cells (APC) secreting IL-4 tend to develop into Th2
cells, while those encountering APC secreting IL-12 tend
to develop into Th1 cells. Interestingly, development of
the Th1 and Th2 phenotypes tend to be mutually exclu-
sive [22,23]. The presence of IL-10 and IL-4 suppresses
development of Th1 cells, while the presence of IL-12 and
IFNγ suppresses the development of Th2 cells. Even estab-
lished responses can be shifted in the presence of the right
cytokine environment. For example, the presence of IL-4
inhibits the development of Th1 cells and shifts Th1
responses to a less-polarized phenotype [24-26].
It is well recognized that in the presence of IL-4 and co-
stimulatory signals from Th2 cells, B lymphocytes are
stimulated to switch to the production of IgE antibodies,
while in the presence of IFNγ, the switch to the production
of IgE is suppressed [27]. The crucial role for these
cytokines in vivo has been demonstrated in mice, where
neutralizing antibodies to IL-4, or administration of IFNγ,
both lead to an inhibition of IgE responses [28]. Also,
transgenic mice homozygous for a mutation that inacti-
vates the IL-4 gene cannot produce IgE. In humans with
hyper-IgE syndrome, the delivery of either IFNγ or IFNγ
leads to a reduction in serum IgE levels [29].
Based on the critical nature of IL-4 and IFNγ for the induc-
tion and suppression of IgE, respectively, we hypothesize
that orally administered PPC is inducing the production
of IFNγ which in turn suppresses IL-4 production and con-
sequently IgE production. We believe that PPC's induc-
tion of IFNγ production is associated with activation of
the Th1 pathway by macrophage and/or dendritic cells
stimulated by PPC to secrete IL-12 and other pro-Th1 fac-BMC Complementary and Alternative Medicine 2009, 9:49 http://www.biomedcentral.com/1472-6882/9/49
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tors. This release of IL-12 and the interaction with Th0
CD4 cells during antigen encounter could lead to the gen-
eration of Th1 CD4 T cells, activation of NK cells, and the
generation of antigen-specific CD8 effector cells, all of
which can then release IFNγ and block the release and the
effects of IL-4. Our finding of enhanced IL-12 and IFNγ
and reduced IL-4 release by PPC treated mice (Figures 5
and 6) support this hypothesis. Further experiments will
be performed to identify the primary cellular targets of
PPC and to determine the mechanisms by which oral
administration of PPC leads to biologically significant
modulation of the Th1/Th2 balance.
Conclusion
Oral delivery of PPC enhances the generation of an anti-
gen-specific CD8+ T cell responses induced by soluble pro-
tein, DNA, and dendritic cell vaccines while at the same
time suppressing the generation of a Th2 dominant IgE
response. This effect on the Th1/Th2 balance was also
observed in aged mice.
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